Qi Liang

This inventor holds 24 USPTO granted patents and 34 published patent applications and 22 EPO patents, primarily in Therapeutic Molecules. Top assignees: Kymab Limited, Atreca, Inc.. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qi Liang. Retrieved from https://idiyas.com/inventor/qi-liang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 34)

% Patents Active = 100.0

EPO Patents = 22 (Patent Applications = 24)

Average Co-Inventor Count = 5.8

ph-index = 13

Forward Citations = 344(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

Areas of Expertise:

PCSK9 Antagonists

Animal Models

Therapeutic Molecules

High-Throughput Screening

Expression Vectors

Anti-Malarial Antibodies

Chimaeric Surrogate Light Chains

Transgenic Mice

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12384855 - PCSK9 antagonists (2025-08-12),

2. 11812731 - Animal models and therapeutic molecules (2023-11-14),

3. 11606941 - Animal models and therapeutic molecules (2023-03-21),

4. 11564380 - Animal models and therapeutic molecules (2023-01-31),

5. 11371042 - Expression vector production and high-throughput cell screening (2022-06-28),

6. 11297810 - Animal models and therapeutic molecules (2022-04-12),

7. 11066464 - Anti-malarial antibodies that bind circumsporozoite protein (2021-07-20),

8. 10774155 - Animal models and therapeutic molecules (2020-09-15),

9. 10337000 - Expression vector production and high-throughput cell screening (2019-07-02),

10. 10226033 - Animal models and therapeutic molecules (2019-03-12),

11. 10165763 - Animal models and therapeutic molecules (2019-01-01),

12. 10064398 - Animal models and therapeutic molecules (2018-09-04),

13. 9963716 - Chimaeric surrogate light chains (SLC) comprising human VpreB (2018-05-08),

14. 9938358 - Animal models and therapeutic molecules (2018-04-10),

15. 9938357 - Animal models and therapeutic molecules (2018-04-10),

Title: Qi Liang: Inspiring the Next Generation of Innovators

Introduction:

Qi Liang, a visionary inventor based in Cambridge, GB, is renowned for his passion for innovation and dedication to creating impactful solutions. With a remarkable 23 patents to his name, Qi Liang's inventive spirit continues to inspire the next generation of inventors worldwide.

Latest Patents:

Among his latest patents is an ingenious invention titled "Animal models and therapeutic molecules." This groundbreaking innovation unveils methods for generating chimaeric human-non-human antibodies and antibody chains, along with fully humanized antibodies. The compositions comprising these antibodies, antibody chains, and derivatives demonstrate Qi Liang's commitment to pioneering advancements in biotechnology.

Career Highlights:

Qi Liang has made significant contributions to the field of biotechnology through his work with prominent companies such as Kymab Limited and Atreca, Inc. His expertise and innovative solutions have propelled these organizations to the forefront of industry advancements, solidifying his reputation as a visionary inventor.

Collaborations:

Throughout his career, Qi Liang has collaborated with esteemed coworkers such as Allan Bradley and E-Chiang Lee. These collaborations have not only fostered a culture of innovation but have also led to the development of groundbreaking technologies that have revolutionized the biotechnology landscape.

Conclusion:

In conclusion, Qi Liang's unwavering dedication to innovation and his relentless pursuit of impactful solutions underscore his status as a trailblazing inventor. His work continues to inspire and shape the future of biotechnology, demonstrating a profound legacy that resonates with inventors and innovators around the globe.

Profile summary based on public USPTO records.